# Intuitive Surgical, Inc. (ISRG) — InvestMoat Analysis

_Last analyzed: August 6, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/isrg_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 84 |
| Growth trajectory | 78 |
| Valuation | 72 |
| **Composite** | **79** |
| **Recommendation** | **Accumulate** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** ISRG
- **Market Cap:** ~$132B

## Moat

The most durable razor-and-blades moat in medical devices — once a hospital installs da Vinci and trains its surgeons, switching is a career-level commitment measured in years, not months.

### The Surgical Flywheel

Intuitive Surgical's moat is built on **Installed Base Lock-In and Surgeon Muscle Memory**:

- **The Surgeon Training Moat:** A surgeon who spends 2-5 years mastering the da Vinci console develops deeply ingrained psychomotor skills that do not transfer to a competing platform. Retraining on Medtronic's Hugo or J&J's Ottava is not a software migration — it is a manual dexterity re-education. Hospitals that switch face surgeon credentialing delays, OR scheduling disruption, and patient outcome uncertainty.
- **Razor-and-Blades at Scale:** Intuitive sells capital equipment (da Vinci systems) at relatively modest margins, then earns 80%+ gross margins on the single-use instruments and accessories that are consumed in every procedure. With 11,710 da Vinci systems in the installed base (June 30, 2026) generating an average of 400+ procedures per year, this creates a durable, inflation-resistant recurring revenue stream that grows automatically with procedure volume.
- **Outcomes Data Network Effect:** Over 14 million da Vinci procedures have generated the world's largest proprietary robotic surgery outcomes database. This data advantage enables faster FDA clearance for new indications, stronger clinical evidence for hospital purchasing committees, and continuous software improvement — a compounding moat that competitors entering the market today cannot replicate for a decade.
- **da Vinci 5 Platform Refresh:** Launched in 2024, da Vinci 5 introduces force feedback, 10,000x more computing power, and AI-assisted surgical guidance. The upgrade cycle refreshes switching cost lock-in for the existing installed base while expanding Intuitive's AI surgery leadership. Each new system sold today embeds Intuitive deeper into hospital infrastructure for the next 10-15 years.

**Moat verdict:** AI is a net tailwind for Intuitive Surgical. Unlike software companies where AI threatens to commoditize the product, AI strengthens Intuitive's moat by adding guided surgery intelligence on top of the installed base — creating a new monetization layer without displacing the physical lock-in. The primary competitive risk is not AI but well-funded platform challengers (Medtronic, J&J) in the next 5-10 years.

## Growth

No new earnings since the July 16 Q2 2026 beat: revenue $2.89B (+19% YoY), worldwide procedures +16% (da Vinci +15%, Ion +36%), non-GAAP EPS $2.80 (+28%) on a 42% non-GAAP operating margin, 468 da Vinci systems placed (246 dV5), installed base 11,710 (+12%). The print beat, but full-year da Vinci procedure guidance of 13.5–15.5% — below the 17–20% pace of FY2025 — signaled deceleration, with US procedure growth moderating to ~12% as benign categories are deferred. Shares fell to ~$345 on July 17 and bottomed near $332 on July 23; by August 6 they had recovered to ~$375 with no incremental fundamental print. Q3 results are the next catalyst. dV5 upgrade momentum and Ion still underwrite low-to-mid-teens growth, but the ~20% procedure-growth era is moderating.

- **Revenue CAGR estimate:** 13-17%
- **Primary type:** both
- **Margin trend:** expanding
- **Key risk (moderate):** US benign-procedure deferrals persist and full-year procedure growth settles below 13.5%, or Medtronic Hugo (US urology cleared Dec 2025) and J&J Ottava take general-surgery share, compressing ISRG's premium multiple further through 2027.
- **Drivers:**
  - da Vinci Procedures — Q2 2026 procedures +15% YoY; US moderating to ~12%; FY guide 13.5–15.5% (decelerating)
  - Ion Platform — Q2 2026 Ion procedures +36% YoY; 55 systems placed; installed base 1,096 (+21%) (stable)
  - Non-GAAP EPS — Q2 2026 EPS $2.80 +28% YoY; 42% op margin — next print Q3 (stable)
- **Score derivation:** Base 80 (15% blended CAGR from guided procedure deceleration and Street fade) + trajectory (−1.3: da Vinci decelerating, Ion and EPS stable) + margin expanding (+4) − competitive/deceleration risk moderate (−5) = 78

## Valuation

At ~$375 (August 6, 2026), ISRG has recovered ~9% from the July 17 post-print close of ~$345 and ~13% from the July 23 low of ~$332 — a partial bounce with no new earnings — but remains ~20% below the June ~$469 peak and ~10% below the $415 base case at a ~$132B market cap. Forward P/E has re-expanded to ~33× (NTM) from the ~31× July lows, still below the historical 40–55× band. Bear ($270) reflects sustained deceleration and share loss to Medtronic Hugo / J&J Ottava; base ($415) assumes 13–15% procedure growth with margins holding ~42%; the bounce narrows but does not close the margin of safety opened by the July de-rating. Street mean target (~$490) sits above our base.

| Multiple | Value | Note |
| --- | --- | --- |
| Trailing P/E (GAAP) | ~43× | $8.72 TTM EPS |
| Forward P/E (NTM) | ~33× | ~$11.3 NTM EPS; FY26E ~$10.79 / FY27E ~$12.01 |
| PEG Ratio | ~2.1× | 33× ÷ ~16% EPS CAGR |
| Price / Sales (NTM) | ~10.6× | ~$12.5B NTM revenue |
| Price / FCF | ~41× | ~$3.22B TTM FCF |

Forward P/E ~33× remains below ISRG's historical 40–55× band after the July de-rating and partial August bounce — cheaper versus its own history, still rich versus the medtech median. PEG ~2.1× is full for mid-teens growth, so the multiple is not a bargain on growth alone. The trailing-to-forward gap (43×→33×) still reflects continued double-digit EPS growth rather than an earnings stumble. _(as of August 2026)_

## Price scenarios

### Bear — $270

Procedure deceleration deepens, competitive platforms take general-surgery share, and the premium multiple compresses toward the market as growth normalizes to double digits.

- US benign-procedure deferrals persist and full-year da Vinci procedure growth settles below 13.5% as elective volumes stay macro-sensitive
- Medtronic Hugo (US urology cleared Dec 2025) and J&J Ottava gain traction in general surgery, pressuring da Vinci ASPs and slowing placements
- dV5 gross-margin mix plus tariff exposure caps operating-margin expansion, and rising R&D spend compresses earnings leverage
- Forward multiple de-rates toward ~23× on 2027 EPS as the ~20% procedure-growth premium is repriced out

### Base — $415

Procedure volume grows 13–15% through 2027 as the dV5 upgrade cycle continues and Ion scales, with non-GAAP operating margin holding near 42%.

- Full-year da Vinci procedure growth lands in the guided 13.5–15.5% range; international placements offset softer US benign volumes
- dV5 upgrade cycle sustains 1,700+ system placements annually, keeping the installed base compounding above 12%
- Ion procedures continue mid-30s% growth, establishing interventional pulmonology as a durable second vector
- Non-GAAP EPS reaches ~$11.70 in 2027 at a ~35× forward multiple as the multiple partially recovers from the July lows

### Bull — $560

Procedure growth reaccelerates as benign deferrals reverse, dV5 AI-guided surgery gains clinical traction, and the premium multiple re-rates back toward its historical band.

- US elective volumes recover and worldwide procedure growth reaccelerates toward 17%+ as deferred benign cases return
- AI-assisted guidance on da Vinci 5 gains FDA clearance as a clinical decision-support layer, adding a SaaS-like revenue stream on top of instruments
- Ion captures a growing share of the lung-biopsy market, contributing $1B+ in high-margin recurring revenue
- Forward multiple re-rates back toward ~48× on 2027 EPS as double-digit-plus growth durability is re-established

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.